Domestic pd-1 inhibitors have better clinical efficacy in the treatment of hepatocellular carcinoma, and the commonly used ones at present are karelizumab, sindilizumab and tirilizumab. Taking Sindilizumab as an example, the drug has recently been approved to be used in combination with Bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma. Clinical trials have shown that the survival of patients with advanced hepatocellular carcinoma has been significantly improved after treatment with this product, which has better clinical efficacy. Therefore the domestic pd-1 inhibitor has great potential in the treatment of hepatocellular carcinoma. The common adverse reactions of Sindilizumab include fever, anemia, elevated alanine aminotransferase, malaise, decreased white blood cell count, etc. It is prohibited for those who are allergic to this product. Please use the medication as prescribed under the supervision of a physician.